InMed Pharmaceuticals Inc... (INM)
2.72
0.05 (1.91%)
At close: Apr 17, 2025, 3:56 PM
2.59
-4.65%
After-hours: Apr 17, 2025, 05:57 PM EDT
1.91% (1D)
| Bid | 2.5 |
| Market Cap | 3.28M |
| Revenue (ttm) | 1.12B |
| Net Income (ttm) | -4.26B |
| EPS (ttm) | -12.42 |
| PE Ratio (ttm) | -0.22 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 2.87 |
| Volume | 7,118 |
| Avg. Volume (20D) | 484,219 |
| Open | 2.56 |
| Previous Close | 2.67 |
| Day's Range | 2.56 - 2.72 |
| 52-Week Range | 1.72 - 15.70 |
| Beta | 0.55 |
About INM
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it en...
Industry Biotechnology
Sector Healthcare
IPO Date May 5, 2014
Employees 13
Stock Exchange NASDAQ
Ticker Symbol INM
Website https://www.inmedpharma.com
2 months ago
+2.02%
InMed Pharmaceuticals shares are trading higher af...
Unlock content with
Pro Subscription
5 months ago
-15.75%
InMed Pharmaceuticals shares are trading lower after the company reported a year-over-year decrease in Q4 EPS results.
2 months ago · newsfilecorp.com
InMed Pharmaceuticals Announces Granting of Patent for Novel CompoundsMarks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds Patent covers novel analog compounds for therapeutic applications in pain, glaucoma, i...
